Praxis Precision Medicines (NASDAQ: PRAX) reported Q3 EPS of ($2.75), $0.76 worse than the analyst estimate of ($1.99). Revenue for the quarter came in at $302 thousand versus the consensus estimate of $328.56 thousand.

For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.